The similarity between aspirin treatment and the lack of response to epinephrine and the frequency of aspirin resistance in healthy males.
OBJECTIVE
The lack of response of platelets against epinephrine has been discovered with a frequency of 14% to 40% in previous studies. There are studies that have demonstrated the effect of aspirin on platelets may resemble the lack of response to epinephrine. In this study, the extent of the effects of aspirin treatment on aggregation and secretion in healthy males with a lack of response to epinephrine and the frequency of aspirin resistance were investigated.


METHODS
Blood samples were collected at the beginning and at the end of a 10-day aspirin usage in 52 healthy males. Epinephrine, adenosine diphosphate (ADP), collagen, arachidonic acid (AA) and thrombin aggregations, and adenosine triphosphate (ATP) secretion were studied. Participants were assigned to nonresponder (<20%), semiresponder (20%-60%), and responder (>60%) groups, depending on their maximum aggregation responses to epinephrine. Participants who displayed an aggregation to AA at the end of the aspirin treatment were accepted to be aspirin resistant.


RESULTS
Of the 52 participants, 4 were found to be nonresponders and 3 of 52 of the participants were found to be semiresponders. Although the lack of response to epinephrine and aspirin treatment displayed similarities in aggregations using epinephrine, ADP, collagen, and thrombin, they differed in aggregations using AA and for ATP secretion. The ratio of aspirin resistance was determined to be 4:52.


CONCLUSIONS
The observation of AA aggregation in the participants with a lack of response to epinephrine demonstrates that epinephrine nonresponse cannot substitute aspirin treatment. The fact that aspirin resistance is observed in healthy males supports the view that aspirin resistance exists even before the first usage.
Sagdilek
Engin
E
Department of Biophysics, Ege University, Faculty of Medicine, Izmir, Turkey. esagdilek@hotmail.com
Korkmaz
Ahmet
A
Oter
Sukru
S
Avcu
Ferit
F
Topal
Turgut
T
Ozler
Mehmet
M
Uysal
Bulent
B
Nevruz
Oral
O
Beyan
Cengiz
C
Ozluk
Kasim
K
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage*; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D004351:Drug Resistance; D004837:Epinephrine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D013997:Time Factors
D000316:Adrenergic alpha-Agonists; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D004837:Epinephrine